These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1392125)

  • 41. Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis.
    Tokano Y; Kanai Y; Hashimoto H; Okumura K; Hirose S
    Ann Rheum Dis; 1992 Jun; 51(6):781-2. PubMed ID: 1616363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between soluble interleukin-2 receptor levels and modified Rodnan total skin thickness scores in a patient with generalized morphea: a case report.
    Nakai N; Hotta E; Asai J; Katoh N
    Allergol Int; 2013 Sep; 62(3):391-3. PubMed ID: 23880615
    [No Abstract]   [Full Text] [Related]  

  • 43. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
    J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma].
    Speranskiĭ AI; Riazantseva TA; Guseva NG; Melkumova KL; Ivanova SM
    Revmatologiia (Mosk); 1990; (3):11-4. PubMed ID: 2098888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Disseminated circumscribed acleroderma associated with diffuse scleroderma of an acrosclerotic type].
    Ryckmanns F; Konz B
    Hautarzt; 1980 Feb; 31(2):86-90. PubMed ID: 7399900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Systemic sclerosis (scleroderma) without scleroderma].
    Nadashkevych ON
    Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serum protein examinations in scleroderma and Sjoegren syndrome].
    OBLATT E; FEHER L; CSIKI T
    Magy Belorv Arch (1955); 1958; 11(2-3):66-9. PubMed ID: 13599647
    [No Abstract]   [Full Text] [Related]  

  • 49. Detection of anti-Fc gamma R antibodies and different cytokines in sera from patients with systemic sclerosis.
    Szegedi A; Czirják L
    J Am Acad Dermatol; 1996 Jul; 35(1):134. PubMed ID: 8682952
    [No Abstract]   [Full Text] [Related]  

  • 50. [Immunogenetic studies of familial occurrence of progressive systemic scleroderma and circumscribed scleroderma].
    Holzmann H; Schlieter A; Altmeyer P; Kühnl P
    Hautarzt; 1992 Sep; 43(9):548-53. PubMed ID: 1399599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Soluble interleukin-2 receptor levels in serum of patients with demyelinating polyneuropathy associated with monoclonal gammopathy.
    Vrethem M; Skogh T; Ernerudh J; Ekstedt B; Andersen O; Lycke J
    J Neurol Neurosurg Psychiatry; 1993 Jun; 56(6):721-2. PubMed ID: 8509797
    [No Abstract]   [Full Text] [Related]  

  • 53. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis.
    Terras S; Opitz E; Moritz RK; Höxtermann S; Gambichler T; Kreuter A
    Ann Rheum Dis; 2013 Jan; 72(1):144-5. PubMed ID: 22858587
    [No Abstract]   [Full Text] [Related]  

  • 54. Soluble intercellular adhesion molecule-1 in a geographical cluster of scleroderma.
    Pittoni V; Litta A; Squilloni E; Bifferoni E; Priori R; Valesini G
    Br J Rheumatol; 1994 Dec; 33(12):1193-4. PubMed ID: 8000758
    [No Abstract]   [Full Text] [Related]  

  • 55. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
    Steen VD; Engel EE; Charley MR; Medsger TA
    J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Soluble interleukin-2 receptor levels in patients with pulmonary tuberculosis].
    Ito M; Kojiro N; Moriwaki Y; Nishiki M; Shirasaka T; Ishihara H; Aitani M; Nakatsuji Y; Hirose T; Okada M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):25-8. PubMed ID: 2787440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Classification of circumscribed scleroderma. A multicenter study of 286 patients. The Scleroderma Study Group of the Society of Dermatologic Research].
    Hautarzt; 1990 Jan; 41(1):16-21. PubMed ID: 2179167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus.
    Carson CW; Beall LD; Hunder GG; Johnson CM; Newman W
    J Rheumatol; 1993 May; 20(5):809-14. PubMed ID: 7687701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro.
    Kessler-Becker D; Smola S; Krieg T; Eckes B
    Exp Dermatol; 2004 Nov; 13(11):708-14. PubMed ID: 15500643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The fall of blood complement level in pathology. Study of 50 cases].
    Kourilsky O; Peltier AP; de Sèze S
    Nouv Presse Med; 1972 Jul; 1(28):1883-8. PubMed ID: 4115492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.